resulting U-100 draw
- Concentration
- 5 mg/mL
- BAC added
- 1 mL
A modified growth-hormone fragment investigated for obesity. Human development did not establish an authorised obesity treatment or a routine-use protocol.
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleA community-provenance subcutaneous dose from an authenticated research forum, around 250-500 mcg once daily taken fasted. Forum reports only, not a validated or trial-verified schedule.
Vial-aware arithmetic
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 300 mcg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.

Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
resulting U-100 draw
resulting U-100 draw
resulting U-100 draw
Shown in the diagram. Closest of these examples to 25 units.
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Oral and intravenous research formulations were evaluated across early studies
The studies did not establish a subcutaneous research-vial regimen for routine use.
View source300 mcg daily in weeks 1-4 followed by 500 mcg daily in weeks 5-12
This is a community subcutaneous convention, not the oral or intravenous regimen used in the human development programme.
View sourceSubcutaneous reports cluster around 250-500 mcg once daily, taken fasted in the morning (some lower to about 175 mcg when headaches occur); dosing is described in micrograms rather than milligrams, and gelling or cloudiness is managed by adding extra bacteriostatic water, roughly 2-3 mL per 5 mg vial
Forum provenance from an authenticated archive with usernames omitted. Reports agree the injectable dose sits in the microgram range and that onset is slow, needing 8-12 weeks to judge; the subcutaneous route is kept separate from oral troche and topical cream forms rather than interconverted.
View sourceThe human development programme does not support the confident dosing schedules commonly repeated by commercial protocol sites.
This page documents the evidence gap rather than presenting an unsupported injectable schedule.
The reviewed archive supplied handling discussion, not an administration schedule: it describes AOD-9604 as aggregation-prone, proposes solution pH 4-6 and low concentration, and says bacteriostatic-saline compatibility is unknown (raw/expert-posts/ep-lets-stick-together-aggregation.md:244-264, :362-368). These formulation claims do not validate the third-party injection schedule above.
An authenticated research-forum archive records subcutaneous AOD-9604 clustering around 250-500 mcg once daily, taken fasted in the morning, with a few reports lowering to about 175 mcg when headaches appear. The dominant technical theme is anti-gelling: members add extra bacteriostatic water, roughly 2-3 mL per 5 mg vial, and prefill and refrigerate to stop the solution clouding or gelling. Reports agree the dose belongs in the microgram range, that onset is slow at 8-12 weeks, and that the injectable route stays separate from oral troche and topical cream forms rather than being interconverted. Usernames are omitted and the planner above reproduces the arithmetic of the reported quantities rather than validating them.

Shared across protocols
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Select the labelled vial quantity used in the calculation.
View Peppys vialUse only a diluent appropriate to the research method and formulation.
View Peppys BAC waterUse a new sterile device for every entry. Source locally.
Source locallyPlan clean handling and immediate sharps disposal. Source locally.
Source locallyDo not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.